

10/546,132>10/02/2007

=> d his

(FILE 'HOME' ENTERED AT 20:05:31 ON 10 FEB 2007)

FILE 'HCAPLUS' ENTERED AT 20:05:54 ON 10 FEB 2007  
E US20060160999/PN 25

L1 1 S E3

FILE 'REGISTRY' ENTERED AT 20:06:56 ON 10 FEB 2007

L2 1 S 185954-97-6/RN  
L3 1 S 41233-29-8/RN  
L4 1 S 88222-72-4/RN  
L5 1 S 95548-26-8/RN  
L6 1 S 126429-21-8/RN  
L7 1 S 185955-17-3/RN  
L8 1 S 748165-21-1/RN  
L9 7 S L2-L8

FILE 'HCAPLUS' ENTERED AT 20:09:45 ON 10 FEB 2007

L10 121 S L9  
E "185954-97-6"/BI,RN 25  
L11 3 S E3 OR E5  
E "18955-22-0"/BI,RN 25  
E "185955-22-0"/BI,RN 25  
L12 18 S E3 OR E5 OR E16 OR E17 OR E18 OR E19 OR E24 OR E25 OR E28 OR  
E "748165-17-5"/BI,RN 25  
L13 1 S E3 OR E5 OR E6 OR E7 OR E8 OR E9 OR E10 OR E11 OR E13 OR E14  
L14 19 S L11-13  
L15 3 S L10 AND L11

=> s l10 and l14

L16 7 L10 AND L14


L14 ANSWER 1 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2007:69448 HCPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 146:135012  
 TITLE: E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes  
 AUTHOR(S): Czeslick, E.; Struppert, A.; Simm, A.; Sablotzki, A.  
 CORPORATE SOURCE: Department of Anesthesiology and Critical Care  
 Medicine, Martin Luther University Halle, Halle/Saale, 06120, Germany  
 SOURCE: Inflammation Research (2006), 55(11), 511-515  
 CODEN: INREFB; ISSN: 1023-3830  
 PUBLISHER: Birkhaeuser Verlag  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB Objective and design: In this ex vivo laboratory study, we investigated the effects of E5564 (eritoran), a toll-like receptor 4-directed endotoxin antagonist, on intracellular expression of interleukin (IL)-6 and tumor necrosis factor (TNF)- $\alpha$  in lipopolysaccharide (LPS)-stimulated human monocytes assessed by flow cytometry. Material and method: Whole blood samples from 10 healthy volunteers (average age: 32 $\pm$ 2 years) were pre-incubated with 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1 and 10ng/mL E5564 for 45 min and after this stimulated with LPS (0.2ng/mL), a dose we the most effective for stimulation. Samples were incubated for 3 h at 37 and 5 % CO<sub>2</sub>. Intracellular expression of IL-6 and TNF- $\alpha$  was assessed by flow cytometry. Results: Our investigation showed that E5564 (0.03 ng/mL up to 10ng/mL) caused a dose-dependent inhibitory effect on IL-6 and TNF- $\alpha$  production in LPS-stimulated human monocytes. Conclusions: The results of this investigation led us to conclude that E5564 has a remarkable LPS inhibitory activity manifested via down-regulation of the intracellular generation of pro-inflammatory cytokines IL-6 and TNF- $\alpha$  in human monocytes.

IT 185955-34-4, Eritoran  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (E5564; Eritoran inhibits lipopolysaccharide-induced cytokine production in human blood monocytes)  
 RN 185955-34-4 HCPLUS  
 CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A





L14 ANSWER 2 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2006:779599 HCPLUS <<LOGINID::20070210>>  
 TITLE: Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury  
 Shimamoto, Akira; Chong, Albert J.; Yada, Masaki;  
 Shomura, Shin; Takayama, Hiroo; Fleisig, Ani J.;  
 Agnew, Matthew L.; Hampton, Craig R.; Rothnie,  
 Christine L.; Spring, Denise J.; Pohlman, Timothy H.;  
 Shimpou, Hideto; Verrier, Edward D.  
 CORPORATE SOURCE: Department of Thoracic & Cardiovascular Surgery, Mie University Graduate School of Medicine, Tsu, Japan  
 SOURCE: Circulation (2006), 114(1, Suppl.), I/270-I/274  
 CODEN: CIRCAZ; ISSN: 0009-7322  
 PUBLISHER: Lippincott Williams & Wilkins  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Background-We previously reported that the functional mutation of Toll-like receptor 4 (TLR4) in C3H/HeJ mice subjected to myocardial ischemia-reperfusion (MI/R) injury resulted in an attenuation of myocardial infarction size. To investigate the ligand-activating TLR4 during MI/R injury, we evaluated the effect of eritoran, a specific TLR4 antagonist, on MI/R injury, with the goal of defining better therapeutic options for MI/R injury. Methods and Results-C57BL/6 mice received eritoran (5 mg/kg) i.v. 10 min before 30 min of in situ of transient occlusion of the left anterior descending artery, followed by 120 min of reperfusion. Infarct size was measured using triphenyltetrazoliumchloride staining. A c-Jun NH<sub>2</sub>-terminal kinase (JNK) activation was determined by Western blotting, nuclear factor (NF)- $\kappa$ B activity was detected by gel-shift assay, and cytokine expression was measured by RNase protection assay. Mice treated with eritoran developed significantly smaller infarcts when compared with mice treated with vehicle alone (21.0 $\pm$ 6.4% vs. 30.9 $\pm$ 13.9%; P=0.041). Eritoran pretreatment resulted in a reduction in JNK phosphorylation (eritoran vs. vehicle: 3.98 $\pm$ 0.81 vs. 7.01 $\pm$ 2.21-fold increase; P=0.020), less nuclear NF- $\kappa$ B translocation (2.70 $\pm$ 0.35 vs. 7.75 $\pm$ 0.60-fold increase; P=0.00007), and a decrease in cytokine expression (P<0.05). Conclusions-We conclude that inhibition of TLR4 with eritoran in an in situ murine model significantly reduces MI/R injury and markers of an inflammatory response.  
 IT 185955-34-4, Eritoran  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibition of Toll-like receptor 4 with eritoran reduces infarcts)

size, c-Jun NH<sub>2</sub>-terminal kinase phosphorylation, nuclear NF-  $\kappa$ B translocation, cytokine expression in myocardial ischemia-reperfusion injury mouse model)


RN 185955-34-4 HCAPLUS

CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:374622 HCAPLUS <<LOGINID::20070210>>

DOCUMENT NUMBER: 145:63104

TITLE: Syntheses of glucose derivatives of E5564-related compounds and their LPS-antagonistic activities


AUTHOR(S): Shiozaki, Masao; Iwano, Yuji; Doi, Hiromi; Tanaka, Daisuke; Shimozato, Takaichi; Kurakata, Shin-ichi

CORPORATE SOURCE: Chemistry Department, Chemtech Laboratories, Inc., Hiromachi 1-2-58, Shinagawa-ku, Tokyo, 140-8710, Japan

SOURCE: Carbohydrate Research (2006), 341(7), 811-822

CODEN: CRBRAT; ISSN: 0008-6215

PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 145:63104  
GI



I

AB Glucose analogs, e.g. I, of E5564 were synthesized, and their LPS-antagonistic activities were measured. The antagonistic activities (IC50) on LPS-induced TNF $\alpha$  production of these compds. toward human whole blood were in the range of 0.9-72.8 nM. Inhibitory doses (ID50) of title compds. on TNF $\alpha$  production induced by co-injection of galactosamine and LPS in C3H/HeN mice in vivo were in the range of 0.9-1.6 mg/kg.

IT 185955-34-4DP, derivs.

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(syntheses of glucose derivs. of E5564-related compds. and their LPS-antagonistic activities)


RN 185955-34-4 HCAPLUS

CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




— (CH<sub>2</sub>)<sup>10</sup> Me

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:411058 HCPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 142:441922  
 TITLE: Antiendotoxin compounds for prevention and treatment of endotoxemia and related complications associated with surgery  
 INVENTOR(S): Lynn, Melvyn  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 6 pp., Cont.-in-part of U.S. Ser. No. 169,628, abandoned.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101549	A1	20050512	US 2004-844265	20040512
WO 2001051060	A1	20010719	WO 2001-US1273	20010112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2004127456	A1	20040701	US 2003-169628	20030507
PRIORITY APPLN. INFO.:			US 2000-176142P	P 20000114
			WO 2001-US1273	W 20010112
			US 2003-169628	B2 20030507

OTHER SOURCE(S): MARPAT 142:441922  
 GI



AB This invention provides methods of preventing and treating endotoxemia and related complications associated with surgical procedures, such as cardiac surgical procedures, by administration of an antiendotoxin compound especially I.

IT 185955-34-4


RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antiendotoxin compound for prevention and treatment of endotoxemia and  
related complications associated with surgery)

RN 185955-34-4 HCAPLUS

α-D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



— (CH<sub>2</sub>)<sub>10</sub> Me

L14 ANSWER 5 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:283289 HCPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 142:329861  
 TITLE: Methods using lipopolysaccharides for treating severe acute respiratory syndrome  
 INVENTOR(S): Rossignol, Daniel P.  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 12 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027826	A2	20050331	WO 2004-US22123	20040712
WO 2005027826	A3	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006276431	A1	20061207	US 2006-331068	20060113
PRIORITY APPLN. INFO.:			US 2003-486444P	P 20030714
			WO 2004-US22123	A1 20040712
OTHER SOURCE(S): GI	MARPAT	142:329861		



AB The invention provides methods for treating severe acute respiratory syndrome (SARS) with lipopolysaccharides, e.g. I.

IT 185955-34-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lipopolysaccharides for treatment of severe acute respiratory syndrome)


RN 185955-34-4 HCAPLUS

CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



— (CH<sub>2</sub>)<sub>10</sub> Me

L14 ANSWER 6 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:756610 HCPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 141:265982  
 TITLE: Compositions for preventing and treating  
 endotoxin-related diseases  
 INVENTOR(S): McShane, James  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078142	A2	20040916	WO 2004-US6713	20040305
WO 2004078142	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004218358	A1	20040916	AU 2004-218358	20040305
CA 2516629	A1	20040916	CA 2004-2516629	20040305
EP 1601661	A2	20051207	EP 2004-718037	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008077	A	20060214	BR 2004-8077	20040305
CN 1780824	A	20060531	CN 2004-80011770	20040305
JP 2006519872	T	20060831	JP 2006-509152	20040305
US 2006222655	A1	20061005	US 2005-547599	20050901
NO 2005004346	A	20051104	NO 2005-4346	20050920
PRIORITY APPLN. INFO.:			US 2003-452022P	P 20030305
			WO 2004-US6713	A 20040305

AB The invention provides pharmaceutical compns. for preventing and treating endotoxin-related diseases and conditions, as well as methods for making and using such compns. containing E 5564, and antioxidants, e.g., BHA, BHT, Pr gallate. A single dose is administered by inhalation 1 µg-24 mg. In the case of acute administration the treatment is carried out for days.  
 IT 185955-34-4  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compns. for preventing and treating endotoxin-related diseases)


RN 185955-34-4 HCPLUS

CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L14 ANSWER 7 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:718552 HCPLUS &lt;&lt;LOGINID::20070210&gt;&gt;

DOCUMENT NUMBER: 141:225771

TITLE: Reagents and methods for preparing lipopolysaccharides antagonist B1287 and stereoisomers thereof for treatment of various forms of septic shock

INVENTOR(S): Fan, Rulin

PATENT ASSIGNEE(S): Eisai Co, Ltd., Japan

SOURCE: PCT Int. Appl., 175 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

WO 2004074303	A2	20040902	WO 2004-US4921	20040218
WO 2004074303	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2006518394	T	20060810	JP 2006-503710	20040218
US 2006160999	A1	20060720	US 2005-546132	20051212
PRIORITY APPLN. INFO.:			US 2003-448839P	P 20030220
			WO 2004-US4921	W 20040218

OTHER SOURCE(S): CASREACT 141:225771; MARPAT 141:225771

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention provides methods for preparing lipopolysaccharides (LPS) antagonist lipo-disaccharide B1287 and stereoisomers thereof, which compds. are useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock (no biol. data). Also provided are synthetic intermediates useful for implementing the inventive methods. Thus, lipo-disaccharide B1287 I was prepared for treatment of various forms of septic shock.

IT 185954-97-6P 185955-22-0P 185955-28-6P  
185955-29-7P 185955-32-2P 185955-34-4P  
748165-17-5P 748165-18-6P 748165-19-7P  
748165-20-0P 748165-22-2P 748165-23-3P  
748165-24-4P 748165-25-5P 748165-26-6P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(reagents and methods for preparing lipopolysaccharides antagonist b and stereoisomers thereof for treatment of various forms of septic shock)

RN 185954-97-6 HCPLUS


CN  $\alpha$ -D-Glucopyranose, 6-O- [4-O- [bis(2-propenyl)phosphinyl]-2-deoxy-3-O- [(3R)-3-methoxydecyl]-6-O-methyl-2- [(11Z)-1-oxo-11-octadecenyl]amino]- $\beta$ -D-glucopyranosyl]-3-O-decyl-2-deoxy-2- [(1,3-dioxotetradecyl)amino]-, 1-(di-2-propenyl phosphate) 4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 185955-22-0 HCPLUS  
 CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 2-amino-3-O-decyl-2-deoxy-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 185955-28-6 HCPLUS  
 CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-6-O-[(1,1-

dimethylsilyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]-, 4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 185955-29-7 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-, 4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

Double bond geometry as shown.





RN 185955-32-2 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 6-O-[4-O-[bis(2-propenyl)phosphoryl]2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]- $\beta$ -D-glucopyranosyl]-3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)aminol]-, 4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

Double bond geometry as shown.




RN 185955-34-4 HCPLUS

CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 748165-17-5 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 748165-18-6 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-, 4-(di-2-propenyl phosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 748165-19-7 HCPLUS

CN D-Glucose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino-, 4-(di-2-propenyl phosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN ✓ 748165-20-0 HCPLUS

CN  $\alpha$ -D-Glucopyranose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino-, 4-(di-2-propenyl phosphate) 1-(2,2,2-trichloroethanimidate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 748165-22-2 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-4,6-O-(1-methylethylidene)-2-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 748165-23-3 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-2-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 748165-24-4 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-2-[(1,3-

dioxotetradecyl)amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 748165-25-5 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decy1-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.





RN 748165-26-6 HCPLUS

CN  $\alpha$ -D-Glucopyranose, 6-O-[4-O-[bis(2-propenyloxy)phosphoryl]-2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[[(11Z)-1-oxo-11-octadecenyl]amino]- $\beta$ -D-glucopyranosyl]-3-O-decy1-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L14 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:698142 HCAPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 141:200225  
 TITLE: Methods and kits for use in the diagnosis and  
 treatment of endotoxemia with a toll-like receptor 4  
 antagonist  
 INVENTOR(S): Rossignol, Daniel P.; Lynn, Melvyn  
 PATENT ASSIGNEE(S): Eisai Co., Ltd, Japan  
 SOURCE: PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071465	A2	20040826	WO 2004-US4552	20040212
WO 2004071465	A3	20050210		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,  
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG

US 2006051821 A1 20060309 US 2005-545136 20050810  
 PRIORITY APPLN. INFO.: US 2003-446891P P 20030212  
 WO 2004-US4552 W 20040212

AB The invention provides methods and kits for use in determining whether a patient may benefit from treatment with a toll-like receptor 4 (TLR4) antagonist, e.g. an antiendotoxin compound

IT 185955-34-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methods and kits for diagnosis and treatment of endotoxemia with toll-like receptor 4 antagonist)


RN 185955-34-4 HCPLUS

CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




L14 ANSWER 9 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2003:132972 HCPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 138:163604  
 TITLE: Treatment and prevention of heat shock  
 protein-associated diseases and conditions with Lipid  
 A analogs  
 INVENTOR(S): Kobayashi, Seiichi; Zhang, Minghuang; Shirota, Hiroshi  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013440	A2	20030220	WO 2002-US25452	20020812
WO 2003013440	A3	20030703		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1420798	A2	20040526	EP 2002-757067	20020812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2004254128	A1	20041216	US 2004-486455	20040726
PRIORITY APPLN. INFO.:			US 2001-311325P	P 20010810
			WO 2002-US25452	W 20020812


OTHER SOURCE(S): MARPAT 138:163604  
 AB The invention provides methods of treating and preventing heat shock  
 protein-associated diseases and conditions.  
 IT 185955-34-4  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (treatment and prevention of heat shock protein-associated diseases and  
 conditions)  
 RN 185955-34-4 HCPLUS  
 CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L14 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:516677 HCAPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 137:57599  
 TITLE: Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of anti-endotoxin drugs  
 INVENTOR(S): Rossignol, Daniel P.; Vermeulen, Mary W.  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: U.S., 37 pp., Cont.-in-part of U.S. 293,856.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6417172	B1	20020709	US 1999-449601	19991123
US 5750664	A	19980512	US 1995-461675	19950605
US 5935938	A	19990810	US 1996-658656	19960605
US 6184366	B1	20010206	US 1999-293856	19990416
CA 2392356	A1	20010531	CA 2000-2392356	20001122
WO 2001037843	A1	20010531	WO 2000-US32177	20001122

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

OTHER SOURCE(S) : MARPAT 137:57599

MARPAT 137:57599

GI



AB Disaccharide compds. I, wherein R is H, CH<sub>2</sub>OH, alkoxide; R1 is acyl; R2 is C<sub>5</sub>-C<sub>15</sub> alkyl R3 is C<sub>5</sub>-C<sub>18</sub> alkyl, acyl, R4 is C<sub>4</sub>-C<sub>20</sub> alkyl, oxyalkyl; A<sub>1</sub> and A<sub>2</sub> are independently OH, phosphate, phosphonate, ester; were prepared for and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin. The invention provides methods of preventing and treating pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin and related conditions in a patient by administering to the patient anti-endotoxin compds. by inhalation. The invention provides methods of preventing and treating pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin and related conditions in a patient by administering to the patient anti-endotoxin compds. by inhalation. Thus, disaccharide lipid II was prepared and tested in mice and suppressed the production of TNF following administration of LPS.

IT 185955-22-0P 185955-28-6P 185955-29-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of anti-endotoxin drugs such as disaccharide lipid A analogs in relation to inhibition of cytokine production)

RN 185955-22-0 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 2-amino-3-O-decyl-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 185955-28-6 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]-, 4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 185955-29-7 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-, 4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2001:617837 HCPLUS <<LOGINID::20070210>>  
DOCUMENT NUMBER: 135:185478  
TITLE: Micelles for drug delivery  
INVENTOR(S): McShane, James; Arens, Tori; Kaneko, Kazuhiro;  
Watanabe, Tomohiro; Ashizawa, Kazuhide  
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060382	A1	20010823	WO 2001-US5297	20010220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2400371	A1	20010823	CA 2001-2400371	20010220
EP 1274443	A1	20030115	EP 2001-910952	20010220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003522797	T	20030729	JP 2001-559478	20010220
US 2003216331	A1	20031120	US 2002-204227	20021003
US 6906042	B2	20050614		
US 2005181039	A1	20050818	US 2005-106654	20050415
PRIORITY APPLN. INFO.:			US 2000-183768P	P 20000218
			WO 2001-US5297	W 20010220
			US 2002-204227	A1 20021003

OTHER SOURCE(S) : MARPAT 135:185478  
GI





I

AB The present invention provides micelles, solns. comprising micelles, methods for preparing micelles, and methods for delivering micelles to patients. The micelles have fixed, preselected hydrodynamic diams. and are formed from basic or acidic amphiphilic compds. Micelles were prepared from E5564 (I) and NaOH solution  
IT 185955-34-4, E5564  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (micelles for drug delivery)  
RN 185955-34-4 HCAPLUS  
CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O- [2-deoxy-3-O- [(3R)-3-methoxydecyl]-6-O-methyl-2- [(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2- [(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A






REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:525928 HCAPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 135:117254  
 TITLE: Antiendotoxin compound for prevention and treatment of endotoxemia and related complications associated with surgery  
 INVENTOR(S): Lynn, Melvyn  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051060	A1	20010719	WO 2001-US1273	20010112
W: AE, AG, AL, CR, CU, CZ, HU, ID, IL, LU, LV, MA, SD, SE, SG, YU, ZA, ZW, RW: GH, GM, KE, DE, DK, ES, FI, BJ, CF, CG,	AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2392731	A1	20010719	CA 2001-2392731	20010112
EP 1250141	A1	20021023	EP 2001-942301	20010112
R: AT, BE, CH, IE, SI, LT,	DE, DK, ES, FR, FI, RO, MK,	GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL, TR		
JP 2003524638	T	20030819	JP 2001-551484	20010112
US 2004127456	A1	20040701	US 2003-169628	20030507
US 2005101549	A1	20050512	US 2004-844265	20040512
PRIORITY APPLN. INFO.:			US 2000-176142P	P 20000114
			WO 2001-US1273	W 20010112
			US 2003-169628	B2 20030507

OTHER SOURCE(S): MARPAT 135:117254  
 GI



AB The invention provides methods of preventing and treating endotoxemia and related complications associated with surgical procedures, e.g. cardiac surgical procedures, by administration of an antiendotoxin compound, e.g. I.

IT 185955-34-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiendotoxin compound for prevention and treatment of endotoxemia and related complications associated with surgery)


RN 185955-34-4 HCPLUS

CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:396678 HCAPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 135:528  
 TITLE: Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs  
 INVENTOR(S): Rossignol, Daniel P.; Vermeulen, Mary W.  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037843	A1	20010531	WO 2000-US32177	20001122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6417172	B1	20020709	US 1999-449601	19991123
CA 2392356	A1	20010531	CA 2000-2392356	20001122
EP 1248629	A1	20021016	EP 2000-980723	20001122
EP 1248629	B1	20050126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003514862	T	20030422	JP 2001-539457	20001122
AT 287719	T	20050215	AT 2000-980723	20001122
HK 1051490	A1	20050422	HK 2003-102773	20030416
PRIORITY APPLN. INFO.:			US 1999-449601	A2 19991123
			US 1995-461675	A2 19950605
			US 1996-658656	A1 19960605
			US 1999-293856	A2 19990416
			WO 2000-US32177	W 20001122

OTHER SOURCE(S): MARPAT 135:528

AB The invention provides methods of preventing and treating pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin and related conditions in a patient by administering to the patient antiendotoxin compds. by inhalation.

IT 185955-22-0P 185955-28-6P 185955-29-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs such as lipid A analogs in relation to inhibition of cytokine production)

RN 185955-22-0 HCAPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 2-amino-3-O-decyl-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 185955-28-6 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]-, 4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 185955-29-7 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-, 4-(2-propenyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:493384 HCAPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 133:109978  
 TITLE: Administration of an anti-endotoxin drug by  
 intravenous infusion  
 INVENTOR(S): Rossignol, Daniel P.; Lynn, Melvyn; Kerns, William D.  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041703	A1	20000720	WO 2000-US1043	20000114
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2359478	A1	20000720	CA 2000-2359478	20000114
EP 1158990	A1	20011205	EP 2000-904375	20000114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534471	T	20021015	JP 2000-593313	20000114
US 2003130212	A1	20030710	US 2002-171465	20020613
US 2005215517	A1	20050929	US 2004-10550	20041213
PRIORITY APPLN. INFO.:			US 1999-116202P	P 19990114
			WO 2000-US1043	W 20000114
			US 2001-889274	B2 20010712
			US 2002-171465	A1 20020613
			WO 2003-US18678	A1 20030613

AB The invention provides methods for administering an anti-endotoxin drug, E5564, by i.v. infusion. The methods can be used for treating conditions such as endotoxemia, sepsis, and septic shock. A pharmaceutical vial contained E5564 100 µg, sodium dihydrogen phosphate tetrahydrate 0.35, sodium hydroxide 0.06, lactose 100, disodium hydrogen phosphate heptahydrate 0.45 mg, and water q.s. 1 mL. Administration of 0.1 mg/kg E5564 to dogs was completely effective in blocking lipopolysaccharide challenge.

IT 185955-34-4, E 5564

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(administration of anti-endotoxin drug by i.v. infusion)

RN 185955-34-4 HCAPLUS

CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2000:161554 HCAPLUS <<LOGINID::20070210>>

RECEIPT NUMBER: 2000-10455  
DOCUMENT NUMBER: 132:212838

TITLE: A method for evaluating lipid A analog-containing injections

## INVENT

INVENTOR(S): Kaneko, Kazuhiro; watanabe, Tomonito; Asai, Yasuyuki; Sano, Yoshihisa; Kikuchi, Kiyomi; Kushida, Ikuo; Ashizawa, Kazuhide

PATENT ASSIGNEE(S): Eisai Co., Ltd, Japan  
SOURCE: PCT Int. N. 16

SOURCE: PCT Int. Appl., 49 pp.  
SODEN, RICHARD

DOCUMENT THREE

DOCUMENT TYPE: Patent  
LANGUAGE

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000013029	A1	20000309	WO 1999-JP4615	19990826
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1111390	A1	20010627	EP 1999-940501	19990826

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

US 6828155 B1 20041207 US 2001-786060 20010301  
PRIORITY APPLN. INFO.: JP 1998-246862 A 19980901  
WO 1999-JP4615 W 19990826

OTHER SOURCE(S) : MARPAT 132:212838

AB A method is provided for evaluating the pharmaceutical injections containing lipid A analog or its pharmacol. acceptable salt by measuring their membrane fluidity and/or CD. This method is utilized upon manufacturing these injections. Methods are also provided for predicting and evaluating the in vivo dynamics of the lipid A analog with respect to these injections by measuring their membrane fluidity and/or CD. The membrane fluidity is measured by a fluorescence probe method using an order parameter (S) and/or a fluorescence polarity (P) and/or a fluorescence anisotropy. The sodium hydroxide concentration used upon dissolving a lipid A analog for injections was optimal at 0.001-0.01M for the guaranteed in vivo dynamics based on these parameters.

IT 185955-34-4

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for evaluating lipid A analog-containing injections)


RN 185955-34-4 HCAPLUS


14. 105955-31-1 (CA INDEX NAME)  
CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-, 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

### Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A






REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 16 OF 19 HCPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1999:779618 HCPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 132:216469  
 TITLE: Quantitative determination of a potent  
 lipopolysaccharide antagonist, E5564, in rat and dog  
 plasma by high-performance liquid chromatography with  
 fluorescence detection  
 AUTHOR(S): Kaneko, K.; Ueda, R.; Kikuchi, K.; Sano, Y.;  
 Yoshimura, T.  
 CORPORATE SOURCE: Tsukuba Research Laboratories, Eisai Co. Ltd.,  
 Ibaraki, Japan  
 SOURCE: Journal of Chromatography, B: Biomedical Sciences and  
 Applications (1999), 736(1 + 2), 67-75  
 CODEN: JCBBEP; ISSN: 0378-4347  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The assay method was established for the quantification of a potent  
 lipopolysaccharide (LPS) antagonist, E5564, in rat and dog plasma using  
 HPLC. E5564 and the I.S. (an analog of E5564) were extracted and derivatized  
 with 9-anthryldiazomethane (ADAM reagent) to be given fluorescence. LC-MS  
 anal. indicated that single mol. of E5564 was coupled with two mols. of  
 ADAM reagent at one on each of the phosphorus groups. After solid-phase  
 extraction, ADAM derivs. of E5564 and the I.S. were separated on an ODS column  
 using methanol/ethanol containing sodium acetate as a mobile phase at 1.2  
 mL/min (gradient elution), and detected by a fluorescence detector  
 (excitation: 254 nm, emission: 415 nm). The intra-day and inter-day  
 precision were less than 14.4%, and accuracy were within  $\pm 13.0\%$  in the  
 concentration range of 30 to 20,000 ng/mL plasma in both species. E5564 was  
 stable for at least 13 days in rat and dog plasma at -20°, and the  
 processed sample was stable for up to 14 days at 4°. This  
 validated method was successfully applied to the evaluation of the  
 pharmacokinetics of E5564 in rats and dogs after single bolus i.v. doses.  
 IT 185955-34-4  
 RL: ANT (Analyte); BPR (Biological process); BSU (Biological study,  
 unclassified); ANST (Analytical study); BIOL (Biological study); PROC  
 (Process)  
 (determination and pharmacokinetics of a potent lipopolysaccharide antagonist,  
 E5564, in blood by HPLC with fluorescence detection)  
 RN 185955-34-4 HCPLUS  
 CN  $\alpha$ -D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-  
 methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-  
 phosphono- $\beta$ -D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-,  
 1-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1999:505657 HCAPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 131:130224  
 TITLE: Substituted liposaccharides useful in the treatment and prevention of endotoxemia  
 INVENTOR(S): Christ, William J.; Rossignol, Daniel P.; Kobayashi, Seiichi; Kawata, Tsutomu  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: U.S., 40 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5935938	A	19990810	US 1996-658656	19960605
US 5681824	A	19971028	US 1995-461677	19950605

US 5750664	A	19980512	US 1995-461675	19950605
CA 2223140	A1	19961212	CA 1996-2223140	19960605
ZA 9604666	A	19970311	ZA 1996-4666	19960605
CN 1192216	A	19980902	CN 1996-195890	19960605
CN 1067082	B	20010613		
PT 853627	T	20040531	PT 1996-923234	19960605
ES 2214543	T3	20040916	ES 1996-923234	19960605
US 6184366	B1	20010206	US 1999-293856	19990416
US 6417172	B1	20020709	US 1999-449601	19991123
US 2002028927	A1	20020307	US 2001-774541	20010130
US 2003144503	A1	20030731	US 2002-144670	20020513
US 2003134805	A1	20030717	US 2002-167222	20020611
US 6683063	B2	20040127		
PRIORITY APPLN. INFO.:				
		US 1995-461675	A2 19950605	
		US 1996-658656	A1 19960605	
		US 1999-293856	A2 19990416	
		US 1999-449601	A1 19991123	
		US 2001-774541	B1 20010130	

OTHER SOURCE(S): MARPAT 131:130224  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Novel substituted liposaccharides I ( R1 = acyl; R2 = C5 to C15 alkyl; R3 = C5 to C18 acyl-alkenyl or acyl-alkynyl; R4 = C4 to C20 alkoxy-substituted alkyl; RA = CH2O-X where X is H or alkyl group; A1,A2 = OH, PO4H2, O-alkyl-OPO3H2, etc.) useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock are prepared. Also provided are processes for preparing the compds., e.g. II, and intermediates useful therein. The aminodeoxy disaccharide analogs inhibit tumor necrosis factor production in vivo, exhibiting IC50s between 1.5 nM and 159 nM.

IT 185955-22-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of substituted lipodisaccharides useful in the treatment and prevention of endotoxemia)

RN 185955-22-0 HCPLUS

CN  $\alpha$ -D-Glucopyranoside, (1Z)-1-propenyl 2-amino-3-O-decyl-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT:

17


THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1997:344486 HCAPLUS <<LOGINID::20070210>>  
 DOCUMENT NUMBER: 126:317571  
 TITLE: Preparation of disaccharide lipid A analogs for  
 treating alcoholic liver disease  
 INVENTOR(S): Rossignol, Daniel P.; Thurman, Ronald G.; Christ,  
 William J.; Lewis, Michael D.  
 PATENT ASSIGNEE(S): Eisai Research Institute, USA  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9711708	A1	19970403	WO 1996-US15861	19960927
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
AU 9672543	A	19970417	AU 1996-72543	19960927
US 5952309	A	19990914	US 1996-720131	19960927
PRIORITY APPLN. INFO.:			US 1995-4577P	P 19950929
			US 1995-4795P	P 19951002

OTHER SOURCE(S): MARPAT 126:317571

GI



AB Title lipid A analogs I (R1-R4 = unsatd. lipid acyl; A1, A2 = OPO3H2, OZPO3H2, ZPO3H2, OZCO2H; Z = alkyl; X = alkyl alkoxy; Y = H, OH, halo, alkoxy, acyloxy) were prepared as endotoxin antagonists for treating alc. liver disease. These antagonists compds. are found to inhibit the swift increase in alc. metabolism which typically accompanies ingestion of alc. and which may lead to the pathophysiol. abnormalities associated with alc. liver disease. Thus, disaccharide I [R1 = R3 = COCH2CO(CH2)10Me; R2 = CH2CH2CH(OH)(CH2)6Me, A1 = A2 = OPO(ONa)2; X = MeOCH2; Y = OH] was prepared and tested for the inhibition of tumor necrosis factor (TNF) in vivo in mice (ED50 = 5 µg per mouse).

IT 185954-97-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of aminodeoxy disaccharide lipid A analogs for treating alc. liver disease)

RN 185954-97-6 HCAPLUS

CN α-D-Glucopyranose, 6-O- [4-O- [bis(2-propenyl)phosphinyl]-2-deoxy-3-O- [(3R)-3-methoxydecyl]-6-O-methyl-2- [(11Z)-1-oxo-11-octadecenyl]amino]-β-D-glucopyranosyl]-3-O-decyl-2-deoxy-2- [(1,3-dioxotetradecyl)amino]-, 1-(di-2-propenyl phosphate) 4-(2-propenyl carbonate) (9CI) (CA INDEX